Justin Brogan

Justin Brogan is an associate in the firm’s Business Law department and a member of its Technology and Life Sciences group. Justin works with clients on a wide array of corporate matters, including venture capital and growth equity financings, mergers and acquisitions, capital markets transactions and SEC compliance. He joined Goodwin in 2022.

Justin’s recent representations, among others, include:

Capital Markets and Mergers & Acquisitions:

• Klaviyo in its $659 million initial public offering
• HI-Bio in its up to $1.8 billion sale to Biogen
• DataRobot in its acquisition of Agnostiq
• Ultimate.ai in its sale to Zendesk
• Veracode in its acquisition of Longbow Security
• Xcoding Labs in its sale to Datadog
• Verisma Systems in its acquisition of ScanSTAT Technologies
• Verisma Systems in its acquisition of Olah Healthcare Technology
• Zynerba Pharmaceuticals (Nasdaq: ZYNE) in its sale to Harmony Biosciences (Nasdaq: HRMY)

Private Financings:

• FamilyWell in its $4.25 million Series Seed financing
• Novo Holdings in its $40 million Series E investment in Cleveland Diagnostics
• Mantra Health in its $5 million Series A-1 financing
• LifeArc in its Convertible Note investment in Ozlo Sleep
• Bid Ventures in its SAFE financings

Justin is a member of the Boston Bar Association and Massachusetts LGBTQ Bar Association.

During law school, Justin was the recipient of Goodwin’s Wayne A. Budd & Marian A. Tse Scholarship.